Organogenesis Holdings Inc. (NASDAQ:ORGO - Get Free Report) CEO Gary S. Gillheeney sold 5,585 shares of Organogenesis stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $3.49, for a total value of $19,491.65. Following the completion of the transaction, the chief executive officer now directly owns 3,039,194 shares of the company's stock, valued at $10,606,787.06. This represents a 0.18 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Organogenesis Price Performance
ORGO traded up $0.15 during midday trading on Monday, hitting $3.55. The company had a trading volume of 390,288 shares, compared to its average volume of 841,201. Organogenesis Holdings Inc. has a twelve month low of $2.16 and a twelve month high of $4.70. The company has a market capitalization of $470.66 million, a PE ratio of -59.17 and a beta of 1.73. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09. The firm's 50-day simple moving average is $3.43 and its 200-day simple moving average is $3.00.
Organogenesis (NASDAQ:ORGO - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $0.09 earnings per share for the quarter, beating analysts' consensus estimates of ($0.02) by $0.11. Organogenesis had a negative net margin of 1.62% and a negative return on equity of 2.69%. The business had revenue of $115.18 million during the quarter, compared to analyst estimates of $109.59 million. During the same quarter last year, the business posted $0.02 earnings per share. Equities research analysts predict that Organogenesis Holdings Inc. will post -0.07 EPS for the current fiscal year.
Institutional Investors Weigh In On Organogenesis
A number of institutional investors and hedge funds have recently made changes to their positions in the company. Captrust Financial Advisors acquired a new stake in Organogenesis in the third quarter worth about $36,000. Pallas Capital Advisors LLC acquired a new position in Organogenesis during the 2nd quarter valued at about $38,000. Delap Wealth Advisory LLC bought a new position in shares of Organogenesis in the 2nd quarter valued at about $40,000. Intech Investment Management LLC acquired a new stake in shares of Organogenesis during the 3rd quarter worth approximately $43,000. Finally, Allspring Global Investments Holdings LLC raised its stake in shares of Organogenesis by 4,989.9% during the second quarter. Allspring Global Investments Holdings LLC now owns 15,677 shares of the company's stock worth $44,000 after buying an additional 15,369 shares during the last quarter. Institutional investors own 49.57% of the company's stock.
About Organogenesis
(
Get Free Report)
Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Organogenesis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organogenesis wasn't on the list.
While Organogenesis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
